Study Looks at How Patients Cope with Treatment Related Financial Distress

One of the scariest things about a cancer diagnosis is the looming threat of overwhelming medical bills.

A recent study confirmst that this threat has very real consequences, causing patients to not only cut back on their lifestyles but alter their treatment.

Researchers from North Carolina conducted a survey study of adults being treated for cancer between June 2010 and May 2011 participating in a national copay assistance program and found that nine out of ten used at least one lifestyle-altering strategy to cope with the high costs of cancer care.

Of 174 participants, 89 percent used at least one lifestyle-altering strategy. These strategies included:

  • Spending less on leisure activities (77%)
  • Spending less on basics (57%)
  • Borrowing money (54%)
  • Spending savings (50%)

They also found that 39 percent, or nearly four out of ten used a care-altering strategy, which included:

  • Not filling a prescription (28%)
  • Taking less medication than prescribed (23%)

Ultimately they were able to determine that those patients who are more likely to alter their cancer care are younger patients and patients with lower incomes.

The research team believes that "Screening for and anticipating potentially harmful cost-coping behavior in the oncology clinic is important to reduce patient distress and promote optimal care."

Source: Abstract 161, 2014 Palliative Care in Oncology Symposium

Photo of Dollar Loan by John Nyboer

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap